Results 211 to 220 of about 252,929 (281)
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective This study aimed to systematically observe the clinical manifestations, immune cell subsets, and dynamic changes in serological indicators in patients with myasthenia gravis (MG) before and after efgartigimod (EFG) treatment. Methods We analyzed the baseline data, laboratory parameters, and lymphocyte subset proportions in MG ...
Tiancheng Luo +9 more
wiley +1 more source
Ridesharing and substance use disorder treatment. [PDF]
J Health EconLennon C, Maclean JC, Teltser K.
europepmc +1 more source
Will Memantine Exacerbate Seizures in People With Epilepsy? A Prospective Cohort Study
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective To evaluate whether add‐on memantine would exacerbate seizures in people with epilepsy. Methods This was a prospective cohort study. People with epilepsy diagnosed with cognitive impairment were consecutively invited. Those who agreed were followed up for at least 24 weeks.
Peiyu Wang +7 more
wiley +1 more source
Polysubstance Use Is Not Synonymous With Poly Substance Use Disorder. [PDF]
Am J Public HealthXu KY, Lin LA, Grucza RA.
europepmc +1 more source
Reduced Muscular Carnosine in Proximal Myotonic Myopathy—A Pilot 1H‐MRS Study
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Myotonic dystrophy type 2 (proximal myotonic myopathy, PROMM) is a progressive multisystem disorder with muscular symptoms (proximal weakness, pain, myotonia) and systemic manifestations such as diabetes mellitus, cataracts, and cardiac arrhythmias.
Alexander Gussew +11 more
wiley +1 more source
First-Year Impact of Drug Decriminalization on Mental- and Substance Use Disorder-Related Healthcare Encounters in British Columbia: An Interrupted Time Series Analysis. [PDF]
Can J PsychiatryMohebbian M +4 more
europepmc +1 more source